[
  {
    "ts": null,
    "headline": "Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement",
    "summary": "Henry Schein (HSIC) stock is in focus after the company secured exclusive U.S. distribution rights for CytoChip’s FDA-cleared CitoCBC system, the first cartridge-based CBC device with a CLIA Waiver for point-of-care testing. See our latest analysis for Henry Schein. Investors have reacted positively to the CitoCBC agreement and recent M&A commentary, with the share price up 23.98% over the past 90 days and a 1-year total shareholder return of 8.82%. This suggests improving momentum after a...",
    "url": "https://finnhub.io/api/news?id=31392cf947faa25e0289add166cbf0b4990e66f4219b0ea9f6008696dac9a1e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768529391,
      "headline": "Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement",
      "id": 138147519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "Henry Schein (HSIC) stock is in focus after the company secured exclusive U.S. distribution rights for CytoChip’s FDA-cleared CitoCBC system, the first cartridge-based CBC device with a CLIA Waiver for point-of-care testing. See our latest analysis for Henry Schein. Investors have reacted positively to the CitoCBC agreement and recent M&A commentary, with the share price up 23.98% over the past 90 days and a 1-year total shareholder return of 8.82%. This suggests improving momentum after a...",
      "url": "https://finnhub.io/api/news?id=31392cf947faa25e0289add166cbf0b4990e66f4219b0ea9f6008696dac9a1e6"
    }
  }
]